Characteristics and Outcomes of Adolescents (15–18 Years) with Chronic Myelogenous Leukemia (CML) in Chronic Phase: The Experience of the International Registry of Childhood CML † (2026) Millot F, Froment M, Durocher L, Metzler M, De Moerloose B, Brandalise SR, Borisevich M, et al. Journal article AI in Dermato-Oncology: Diagnostic Performance and Prompt-Injection Vulnerability of Vision–Language Models in Dermoscopic Skin Cancer Assessment (2026) Güler I, Kraus A, Grieb G, Satir T, Eberz P, Stelling H Journal article Extracellular Vesicle-Mediated Delivery of Curcumin Suppresses Tumor Progression in Murine Oral Squamous Cell Carcinoma (2026) Ludwig N, Feldmann C, Spörl S, Yerneni SS Journal article Prognostic Impact of MYC/TP63 Molecular Subtypes in Adenoid Cystic Carcinoma: A Meta-Analysis † (2026) Rao KN, Dange P, Sreeram MP, Coca-Pelaz A, Stenman G, Ferrarotto R, Shetty T, et al. Journal article, Review article Stimulated Raman Spectroscopy for Intraoperative Glioblastoma Diagnosis—A Complementary Tool to Frozen Section? (2026) Sippl C, Stark F, Schneider I, Reyes Medina B, Schulz-Schaeffer W, Brinkmann M, Neumann F, et al. Journal article Machine-Learning-Based Survival Prediction in Glioblastoma Using Graph-Theoretical Analysis of Structural Network Alterations (2026) Stadlbauer A, Oberndorfer S, Heinz G, Marhold F, Kinfe TM, Dorostkar M, Schnell O, et al. Journal article Two-Stage Surgery in Patients with Diffuse Glioma—Indications, Implications and Outcome (2026) Jeising S, Reinken J, Rapp M, Sabel M, Staub-Bartelt F Journal article Prospective Analysis of Multidisciplinary (MDT)-Based Cross-Sectional Imaging to Predict the Histology of Soft Tissue Tumors (BACH-Trial) (2026) Fechner K, Golcher H, Brunner M, Meidenbauer N, Semrau S, Uder M, Weber G, et al. Journal article The Health-Related Quality of Life of German Desmoid Patients: Results from the PROSa-DES and PROSa Study (2026) Eichler M, Hoffmann R, Baumgarten C, Jakob J, Kasper B, Richter S, Pink D, et al. Journal article COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma (2026) Weichenthal M, Debus D, Zimmer L, Wasielewski Iv, Meier F, Tüting T, Heppt M, et al. Journal article